Dermira, Inc.

Quick facts

Phase 3 pipeline

• Olumacostat Glasaretil Gel, 5.0% · Dermatology
  Olumacostat glasaretil inhibits sebum production by blocking sterol O-acyltransferase (SOAT1), reducing lipid accumulation in sebaceous glands.

Phase 2 pipeline

• DRM02 · Immunology
  DRM02 is a monoclonal antibody that targets CD40L.

Phase 1 pipeline

• Olumacostat Glasaretil Gel, 7.5%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dermira, Inc. portfolio CI brief
• Dermira, Inc. pipeline updates RSS